research High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata
CD8+ T cells are involved in alopecia areata and may cause disease relapse.
Search
forLearn
0 / 0 results — no results
Research
5 / 1000+ results
research Changes in Distribution Pattern of CD8 Lymphocytes in the Scalp in Alopecia Areata During Treatment With Diphenylcyclopropenone
Diphencyprone treatment increases CD8 lymphocytes in the scalp, which is associated with hair regrowth in alopecia areata patients.
research Diffuse Alopecia Areata Is Associated With Intense Inflammatory Infiltration and CD8+ T Cells in Hair Loss Regions and an Increase in Serum IgE Level
Diffuse alopecia areata involves more inflammation and higher allergy-related antibodies than patchy types.
research Epigallocatechin-3 Gallate Inhibits STAT-1/JAK2/IRF-1/HLA-DR/HLA-B and Reduces CD8 NKG2D Lymphocytes in Alopecia Areata Patients
EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.
research Diphencyprone and Topical Tacrolimus as Two Topical Immunotherapeutic Modalities: Are They Effective in the Treatment of Alopecia Areata Among Egyptian Patients? A Study Using CD4, CD8, and MHC II as Markers
Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.
Community Join
2 / 2 resultscommunity Mallia Aesthetics achieves key regulatory steps for novel sCD83-derived ingredient for hair growth
Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.